On October 22, 2021, Roche announced the U.S. Food and Drug Administration (FDA) approved its VENTANA PD-L1 (SP263) Assay as a companion diagnostic for patients with non-small cell lung cancer eligible for treatment with atezolizumab.
Read Roche's announcement for more information.
Posted 10/22/2021
From mental health concerns to fertility preservation, adolescents and young adults with cancer require a specialized approach to treatment and survivorship care. In honor of Childhood Cancer Awareness Month, ACCC highlights a pivotal program from the University of North Carolina Lineberger Comprehensive Cancer Center and resources that meet the critical needs of these patients.
